Combination therapy is routinely used to achieve improved cholesterol reduction in familial hypercholesterolaemia. We compared the standard simvastatin plus bile-acid sequestrant ( 
Introduction
Many patients with familial hypercholesterolaemia prove difficult to control on single-agent therapy with a hydroxy-methyl-glutaryl-CoA-reductase inhibitor (HMG-CoAl). Most require additional therapy with a bile-acid sequestrant, but many patients complain of side-effects with these agents, and in addition they interfere with the absorption of other drugs, unless care is taken with the timing of additional medications. In mixed hyperlipidaemia, fibrate-HMG-CoAl regimens have been used in small studies with some success, though there has been resistance to their widespread use following early reports of myopathy with the gemfibrozil-lovastatin and gemfibrozil-simvastatin combinations. In this study, we evaluated our experience with the use of a fenofibrate-simvastatin combination in patients with severe familial hypercholesterolaemia compared with standard simvastatin-cholestyramine therapy.
Methods
The lipid clinics at St. Thomas' include 350 patients with familial hypercholesterolaemia, of whom 52 have particular difficulty in attaining a LDL-cholesterol target of 3.5 mmol/l. We recruited 29 patients aged 18-70 years with severe familial hypercholesterolaemia whose total cholesterols on best treatment were > 7 mmol/l, and who had been prescribed, and were tolerant of, simvastatin therapy. These patients were studied for 6 months involving two visits with combination therapy after initiation of fenofibrate 200 mane plus simvastatin 40 mg nocte combination therapy, and the results compared with previous results achieved on simvastatin 40 mg plus bile-acid sequestrant (cholestyramine 32 g/day) therapy. All results were compared with values after 4 weeks off drug treatment.
Blood samples were taken at each clinic visit and stored at -20 °C until analysed.
Total cholesterol, triglycerides and high-density lipoprotein cholesterol were measured by standard enzymic techniques and following manganesedextran precipitation for HDL-cholesterol. Apolipoprotein A 1 , A2 and B 100 concentrations were determined by turbidimetry on a Cobas Fara II analyser. Possible side-effects of the medications were monitored by questioning patients, and biochemically by measurement of creatine kinase, aspartate transaminase and gamma-glutamyl transferase activities in plasma.
Statistical analysis
Distributions of all variables were analysed using geometric means for the non-normally-distributed variable of triglyceride. Groups of data were compared using paired Student's t tests for the two drug regimes.
Results
The characteristics of patients enrolled in the study, and results obtained, are shown in Table 1 . Both regimes achieved highly significant improvements in the lipid profile compared to pre-treatment values (data not shown). The average reductions in total cholesterol were 29.3 + 13.2% (cholestyramine plus HMG-CoAl therapy) and 35.1 + 1 0 . 7 % (fibrate plus HMG-CoAl therapy). Triglycerides were reduced by 12.5 + 48.9% on cholestyramine therapy and by 17.2+56.5% on fibrate-statin therapy. HDL cholesterol was increased by 5.0 + 25.4% on cholestyramine therapy and by 20.3 + 52.0% on fibrate-statin therapy. The cholestyramine regime gave rise to a significant increase in triglyceride ( p = 0.04) whilst not affecting HDL or apolipoprotein A1 concentrations and was significantly less effective than the fibrate regimen. Both regimens significantly reduced apolipoprotein B concentration, but there was no significant difference between them. The HMG-CoAIfibrate regimen resulted in a significant improvement in the LDL: HDL towards the target ratio of 3.5 (p = 0.046) and in the balance of apolipoproteins involved in forward and reverse cholesterol transport: apolipoprotein B: apolipoprotein A1 ratio (p = 0.05). There was no significant difference between the regimens in particle cholesterol saturation (LDL/apolipoprotein B ratio) or in the atherogenic particle balance as described by the apolipoprotein B:(apolipoprotein A1-apolipoprotein A2) ratio (HDL-3).
The commonest adverse event seen with the combination therapies were gastrointestinal disturbance (nausea, flatus, abdominal pain, diarrhoea or constipation) seen with the cholestyramine therapy (10/29) (28%) whilst myalgia was reported in 4/29 (25%) patients with fibrate therapy. In this family, it was severe enough for the patients to ask to return to their previous poorly-tolerated bile-acid sequestrant therapy on review. No disturbances in liver biochemistry or creatine kinase were seen in either group. No serious adverse events were reported by the patients in either phase of the study.
Discussion
Familial hypercholesterolaemia is associated with a marked increase in cardiovascular risk, and current drug therapy regimens are often insufficient to achieve the secondary or primary prevention lipid targets necessary to increase life expectancy in these patients.
1 " 3 Most studies have relied on the use of combination therapies of bile-acid sequestrant and HMG-CoA reductase inhibitors to achieve additional LDL cholesterol reduction, but these agents are generally poorly tolerated, interfere with the absorption of other medications and have adverse effects on the overall lipid profile. An increase in triglycerides, as is sometimes seen with bile-acid sequestrant therapy, is occasionally associated with a reduction in HDL cholesterol and apolipoprotein A1 levels. 4 ' 5 Above triglyceride concentrations of 1.7mmol/l, larger amounts of small, dense LDL particles (LDL 3) are formed, which are more atherogenic than buoyant LDL particles (LDL 1), 6 and these may represent a deterioration in the overall lipid profile. Triglycerides are associated with increased risk of coronary events post coronary surgery, 7 and many patients with familial hypercholesterolaemia have undergone angioplasty or coronary bypass grafting. Fibrate drugs act via the peroxisomal proliferation pathways to reduce fibrinogen, increase HDL, reduce triglyceride and improve insulin resistance, all of which are associated with improvements in the distribution of LDL subfractions and improvement in the cardiovascular risk profile. 8 Thus these agents, if they can achieve the requisite cholesterol reductions, may have additional benefits compared to standard regimes in familial hypercholesterolaemia. The only concern is the individual case reports of myopathy and rhabdomyolysis seen in early studies of the gemfibrozi I-statin combination but not seen in later studies on these combinations. BECAIT studies) 12 shows that these agents on their own can significantly reduce coronary atheroma progression and cardiovascular events. The combination should achieve the benefits of both agents, as the HMG-CoA reductase inhibitors have little effect on LDL subfraction distribution or HDL, whilst significantly lowering LDL cholesterol and partially reducing VLDL production. The opposite is true for the fibrates, with these drugs having lesser effects on LDL but greater effects on triglycerides, HDL and LDL subfraction distribution. Some studies with bezafibrate-HMG CoA reductase inhibitor combinations have been performed, mostly at low doses of HMG-CoA reductase inhibitor, and these show an further 2-12% incremental reduction in total cholesterol and LDL, 3-30% in triglyceride and -1 0 to 2% increment in HDL with bezafibrate. 9 ' 13 ' 14 The only study performed with fenofibrate, which used ten similar patients to this study, reported similar effects, with an extra 14% reduction in total cholesterol, 22% in LDL, and 26% in triglyceride, but no effect on HDL. 15 That study did not compare the results with the commonly used HMG-CoAl plus resin combination. The only significant side-effect reported in this study was myalgia, with no evidence of biochemical muscle damage or rhabmyolysis in four related patients. This side-effect is often reported with highdose lipid-lowering drug therapy and seems to be associated with reduction in muscle ubiquinone (co-enzyme Q 10 ) concentrations, possibly due to increased sensitivity to the reduction in flux through the cholesterol synthetic pathway. 16 ' 17 In this study, fibrate-statin was superior in tolerability to resin-statin combinations, achieved a similar reduction in total cholesterol, and improved the overall lipid profile with respect to triglyceride reduction, HDL increase and ratios of LDL: HDL without any significant side-effects.
